Morgan Stanley’s Loncar China BioPharma ETF CHNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-188
| Closed | -$2.68K | – | 8037 |
|
|
2023
Q3 | $2.68K | Hold |
188
| – | – | ﹤0.01% | 7064 |
|
|
2023
Q2 | $3.04K | Hold |
188
| – | – | ﹤0.01% | 7100 |
|
|
2023
Q1 | $3.35K | Hold |
188
| – | – | ﹤0.01% | 7146 |
|
|
2022
Q4 | $3.53K | Hold |
188
| – | – | ﹤0.01% | 7239 |
|
|
2022
Q3 | $3K | Hold |
188
| – | – | ﹤0.01% | 7423 |
|
|
2022
Q2 | $4K | Hold |
188
| – | – | ﹤0.01% | 7479 |
|
|
2022
Q1 | $4K | Sell |
188
-2,000
| -91% | -$44.3K | ﹤0.01% | 7655 |
|
|
2021
Q4 | $59K | Hold |
2,188
| – | – | ﹤0.01% | 6738 |
|
|
2021
Q3 | $82K | Hold |
2,188
| – | – | ﹤0.01% | 6483 |
|
|
2021
Q2 | $104K | Hold |
2,188
| – | – | ﹤0.01% | 6344 |
|
|
2021
Q1 | $81K | Buy |
2,188
+188
| +9% | +$7.01K | ﹤0.01% | 6123 |
|
|
2020
Q4 | $65K | Hold |
2,000
| – | – | ﹤0.01% | 6074 |
|
|
2020
Q3 | $61K | Hold |
2,000
| – | – | ﹤0.01% | 5651 |
|
|
2020
Q2 | $61K | Hold |
2,000
| – | – | ﹤0.01% | 5614 |
|
|
2020
Q1 | $45K | Hold |
2,000
| – | – | ﹤0.01% | 5505 |
|
|
2019
Q4 | $50K | Hold |
2,000
| – | – | ﹤0.01% | 5859 |
|
|
2019
Q3 | $44K | Hold |
2,000
| – | – | ﹤0.01% | 5779 |
|
|
2019
Q2 | $44K | Hold |
2,000
| – | – | ﹤0.01% | 5664 |
|
|
2019
Q1 | $48K | Hold |
2,000
| – | – | ﹤0.01% | 5685 |
|
|
2018
Q4 | $38K | Buy |
+2,000
| New | +$41.4K | ﹤0.01% | 5835 |
|
Morgan Stanley's CHNA Position: Q4 2023 in Review
Morgan Stanley sold out of Loncar China BioPharma ETF (CHNA) in Q4 2023, closing a stake of 188 shares — an estimated $2.68K sold.
Morgan Stanley first reported a position in CHNA in Q4 2018 and held it in 20 quarters. The position peaked at $104K in Q2 2021. 0 funds tracked by Wall St. Rank hold CHNA as of Q4 2023.
- Morgan Stanley reported no remaining Loncar China BioPharma ETF position as of Q4 2023 after selling out during the quarter.
- Morgan Stanley sold 188 Loncar China BioPharma ETF shares in Q4 2023, an estimated $2.68K.
- Morgan Stanley first reported a position in Loncar China BioPharma ETF in Q4 2018 and held it in 20 quarters.
- Morgan Stanley's Loncar China BioPharma ETF position peaked at $104K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Loncar China BioPharma ETF as of Q4 2023.
Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.